Middle East & Africa Biopharmaceutical Market Size & Outlook

The biopharmaceutical market in Middle East & Africa is expected to reach a projected revenue of US$ 12,446.1 million by 2030. A compound annual growth rate of 7.7% is expected of Middle East & Africa biopharmaceutical market from 2025 to 2030.
Revenue, 2024 (US$M)
$8,086.2
Forecast, 2030 (US$M)
$12,446.1
CAGR, 2025 - 2030
7.7%
Report Coverage
Middle East & Africa

Middle East & Africa biopharmaceutical market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Middle East & Africa biopharmaceutical market, 2018-2030 (US$M)

MEA biopharmaceutical market highlights

  • The MEA biopharmaceutical market generated a revenue of USD 8,086.2 million in 2024.
  • The market is expected to grow at a CAGR of 7.7% from 2025 to 2030.
  • In terms of segment, monoclonal antibody was the largest revenue generating molecule type in 2024.
  • Hormone is the most lucrative molecule type segment registering the fastest growth during the forecast period.
  • Country-wise, UAE is expected to register the highest CAGR from 2025 to 2030.


MEA data book summary

Market revenue in 2024USD 8,086.2 million
Market revenue in 2030USD 12,446.1 million
Growth rate7.7% (CAGR from 2025 to 2030)
Largest segmentMonoclonal antibody
Fastest growing segmentHormone
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationMonoclonal Antibody, Interferon, Insulin, Growth and Coagulation Factor, Erythropoietin, Vaccine, Hormone


Other key industry trends

  • In terms of revenue, MEA region accounted for 1.8% of the global biopharmaceutical market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 125,350.1 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Biopharmaceutical Market Companies

Name Profile # Employees HQ Website

Middle East & Africa biopharmaceutical market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical market will help companies and investors design strategic landscapes.


Monoclonal antibody was the largest segment with a revenue share of 66.91% in 2024. Horizon Databook has segmented the Middle East & Africa biopharmaceutical market based on monoclonal antibody, interferon, insulin, growth and coagulation factor, erythropoietin, vaccine, hormone covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Middle East & Africa biopharmaceutical market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Middle East & Africa biopharmaceutical market databook

  • Our clientele includes a mix of biopharmaceutical market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa biopharmaceutical market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa biopharmaceutical market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

MEA biopharmaceutical market size, by country, 2018-2030 (US$M)

Middle East & Africa Biopharmaceutical Market Outlook Share, 2024 & 2030 (US$M)

MEA biopharmaceutical market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more